FEATURED COMPANIES
- Abbott Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Novartis AG
- Sanofi SA
- Siemens Healthineers
Global Uterine Cancer Therapeutics and Diagnostics Market to Reach $27.7 Billion by 2027
Amid the COVID-19 crisis, the global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$19.5 Billion in the year 2020, is projected to reach a revised size of US$27.7 Billion by 2027, growing at a CAGR of 5.1% over the period 2020-2027. Uterine Sarcomas, one of the segments analyzed in the report, is projected to record 3.9% CAGR and reach US$9.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Endometrial Carcinomas segment is readjusted to a revised 5.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $5.6 Billion, While China is Forecast to Grow at 8.5% CAGR
The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.1 Billion by the year 2027 trailing a CAGR of 8.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.
Select Competitors (Total 46 Featured):
Amid the COVID-19 crisis, the global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$19.5 Billion in the year 2020, is projected to reach a revised size of US$27.7 Billion by 2027, growing at a CAGR of 5.1% over the period 2020-2027. Uterine Sarcomas, one of the segments analyzed in the report, is projected to record 3.9% CAGR and reach US$9.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Endometrial Carcinomas segment is readjusted to a revised 5.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $5.6 Billion, While China is Forecast to Grow at 8.5% CAGR
The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.1 Billion by the year 2027 trailing a CAGR of 8.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.9% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.
Select Competitors (Total 46 Featured):
- Abbott Laboratories, Inc.
- ARIAD Pharmaceuticals, Inc.
- Becton, Dickinson and Company
- F. Hoffmann-La Roche AG
- Merck & Co., Inc.
- Novartis AG
- Sanofi SA
- Siemens Healthineers
Frequently Asked Questions about the Global Market for Uterine Cancer Therapeutics and Diagnostics
What is the estimated value of the Global Market for Uterine Cancer Therapeutics and Diagnostics?
What is the growth rate of the Global Market for Uterine Cancer Therapeutics and Diagnostics?
What is the forecasted size of the Global Market for Uterine Cancer Therapeutics and Diagnostics?
Who are the key companies in the Global Market for Uterine Cancer Therapeutics and Diagnostics?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Abbott Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Novartis AG
- Sanofi SA
- Siemens Healthineers
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE
1. MARKET OVERVIEW
III. MARKET ANALYSIS
IV. COMPETITION
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Abbott Laboratories, Inc.
- ARIAD Pharmaceuticals, Inc.
- Becton, Dickinson and Company
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- Novartis AG
- Sanofi SA
- Siemens Healthineers
Note: Product cover images may vary from those shown